---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-030776"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:22:07.173447+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences reports CAHmelia-203 fails primary endpoint; cuts 21% workforce

## Summary
- CAHmelia-203 failed primary endpoint; tildacerfont 200mg QD showed -2.6% placebo-adjusted A4 reduction (non-significant).
- Board approved workforce reduction of ~21% and termination of CAHmelia-203; estimated $0.4M cash charges, Q2 2024.
- Pediatric CAHptain-205: 73% of patients met A4 or GC reduction endpoint; more rapid clearance than adults.
- Cash and equivalents $96.3M at Dec 31, 2023; cost reductions extend runway through end of 2025.
- Expects topline CAHmelia-204 in Q3 2024, additional CAHptain-205 data in Q4 2024, FDA meeting in Q1 2025.

## SEC filing metadata
- accession: 0000950170-24-030776
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01, 2.05, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017024030776/0000950170-24-030776-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017024030776/sprb-20240310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-030776
- JSON: https://secwatch.observer/filing/0000950170-24-030776.json
- Plain text: https://secwatch.observer/filing/0000950170-24-030776.txt

## Key facts
- Earnings Releases
  SPRUCE BIOSCIENCES, INC. reported full year ended December 31, 2023 results: revenue $10.1 million, net income $47.9 million.
  - Period: full year ended December 31, 2023
  - Revenue: $10.1 million
  - Net income: $47.9 million
  - Result: reported results
  source text: topline results from CAHmelia-204 and additional dose-ranging data from CAHptain-205. • Collaboration Revenue: Collaboration revenue for the year ended December 31, 2023 was $10.1 million compared to nil in 2022, reflecting the partial recognition of the $15.0 million upfront payment received from Kaken Pharmaceutical (“Kaken”) in connection with the company’s
  evidence_url: https://www.sec.gov/Archives/edgar/data/1683553/000095017024030776/0000950170-24-030776-index.htm
- Restructurings & Charges
  SPRUCE BIOSCIENCES, INC. announced a restructuring with charges of the Company estimates that it will incur approximately $0.4 million in cash charges in connection with the Realignment Plan, consisting of expenses related to e affecting workforce reduction of approximately 21% (workforce reduction of approximately 21%).
  - Type: restructuring
  - Charge: the Company estimates that it will incur approximately $0.4 million in cash charges in connection with the Realignment Plan, consisting of expenses related to e
  - Affected area: workforce reduction of approximately 21%
  - Headcount: workforce reduction of approximately 21%
  source text: and expenditures relating to the Realignment Plan will not be known until all related activities have been completed. The Company estimates that it will incur approximately $0.4 million in cash charges in connection with the Realignment Plan, consisting of expenses related to employee severance payments and healthcare coverage assistance and related costs. The
  evidence_url: https://www.sec.gov/Archives/edgar/data/1683553/000095017024030776/0000950170-24-030776-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.